Likewise, the Checkmate 012 trial, a multicohort clinical trial, demonstrated that first-line nivolumab monotherapy or in combination with standard therapies showed no meaningful activity in NSCLC with EGFR mutations (22). This evidence concerns the gene EGFR and non-small cell lung carcinoma.